How do carriers of pathogenic mtDNA respond to controlled ovarian stimulation (COS)?
This was a single-center; retrospective study carried out from January 2006 to July 2021 in France. We compared ovarian reserve markers and COS outcomes for PGT women patients with maternally inherited mtDNA disease (n=18) (mtDNA-PGT group) to a control-matched patients group (n=96). We also reported the PGT outcomes for the mtDNA-PGT group and the follow up of these patients in case of unsuccessfull PGT.
For carriers of pathogenic mtDNA, parameters of ovarian response to FSH and COS outcomes were not different from those of matched COS cycles. However, the carriers of pathogenic mtDNAneeded a longer ovarian stimulation and higher dose of gonadotropins. Three patients (16.6%) obtained a live birth after the PGT process, and 8 patients (44.4%) obtained a live birth through alternative methods (oocyte donation (n=4), spontaneous pregnancy with PND (n=2), and adoption (n=2)).
We report the first study of women carrying a mtDNA variantwho have undergone a PGT-M procedure. We concluded that PGT is one of the possible options to obtain a healthy baby without observing an impairment in ovarian response to stimulation.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Reproductive BioMedicine Online
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Dr. Anne Mayeur is a medical Embryologist at Clamart Hospital, Paris, France. She graduated in 2013. She is particularly dedicated to PGT-M and PGT-SR activities and conducts research to improve the management of patients with genetic defects.
Accepted: February 20, 2023
Received in revised form: January 18, 2023
Received: October 24, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.